Do you support this bill?

Senate Bill S8633

2023-2024 Legislative Session

Requires notification by a prescriber or pharmacist of the substitution of one generic drug product for another generic drug product

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Senate Committee Higher Education Committee

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

2023-S8633 (ACTIVE) - Details

Current Committee:
Senate Higher Education
Law Section:
Education Law
Laws Affected:
Amd §6810, Ed L
Versions Introduced in 2025-2026 Legislative Session:
S5352

2023-S8633 (ACTIVE) - Summary

Requires notification by a prescriber or pharmacist of the substitution of one generic drug product for another generic drug product; requires both oral and written notification.

2023-S8633 (ACTIVE) - Sponsor Memo

2023-S8633 (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   8633
 
                             I N  S E N A T E
 
                             February 23, 2024
                                ___________
 
 Introduced  by  Sen.  CHU  --  read  twice and ordered printed, and when
   printed to be committed to the Committee on Higher Education
 
 AN ACT to amend the education law, in relation to  notification  of  the
   substitution of one generic drug product for another generic drug
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:

   Section 1. Subdivision 6 of section  6810  of  the  education  law  is
 amended by adding a new paragraph (b-1) to read as follows:
   (B-1) THE PRESCRIBER OR PHARMACIST SHALL INFORM THE PATIENT WHETHER HE
 OR  SHE  HAS  PRESCRIBED OR SUBSTITUTED A DIFFERENT GENERIC DRUG PRODUCT
 FROM THE GENERIC DRUG  PRODUCT  THE  PATIENT  HAS  PREVIOUSLY  RECEIVED.
 NOTIFICATION  REQUIRED PURSUANT TO THIS PARAGRAPH SHALL BE PROVIDED BOTH
 WRITTEN AND ORALLY.
   § 2. This act shall take effect on the ninetieth day  after  it  shall
 have become a law.
 
 
 
 
 
 
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD14465-01-4

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.